A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease

Charles Flicker; Steven H. Ferris; Davina Kalkstein; Michael Serby

doi:10.1176/ajp.151.1.126

A double-blind, placebo-controlled crossover study of ganglioside GM₁ treatment for Alzheimer's disease

Charles Flicker
, Steven H. Ferris
, Davina Kalkstein
, Michael Serby

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM₁) (100 mg/day i.m.), which potentiates the actions of nerve growth factor. GM₁ failed to produce significant improvement in patients' cognitive test performance, suggesting that this is not a viable approach to the treatment of cognitive deterioration in Alzheimer's disease.

Original language	English
Pages (from-to)	126-129
Number of pages	4
Journal	American Journal of Psychiatry
Volume	151
Issue number	1
DOIs	https://doi.org/10.1176/ajp.151.1.126
State	Published - Jan 1994
Externally published	Yes

Access to Document

10.1176/ajp.151.1.126

Cite this

@article{7982e975587f4d0daeee0fcbc3755157,

title = "A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease",

abstract = "In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor. GM1 failed to produce significant improvement in patients' cognitive test performance, suggesting that this is not a viable approach to the treatment of cognitive deterioration in Alzheimer's disease.",

author = "Charles Flicker and Ferris, \{Steven H.\} and Davina Kalkstein and Michael Serby",

year = "1994",

month = jan,

doi = "10.1176/ajp.151.1.126",

language = "English",

volume = "151",

pages = "126--129",

journal = "American Journal of Psychiatry",

issn = "0002-953X",

publisher = "American Psychiatric Association",

number = "1",

}

TY - JOUR

T1 - A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease

AU - Flicker, Charles

AU - Ferris, Steven H.

AU - Kalkstein, Davina

AU - Serby, Michael

PY - 1994/1

Y1 - 1994/1

N2 - In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor. GM1 failed to produce significant improvement in patients' cognitive test performance, suggesting that this is not a viable approach to the treatment of cognitive deterioration in Alzheimer's disease.

AB - In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor. GM1 failed to produce significant improvement in patients' cognitive test performance, suggesting that this is not a viable approach to the treatment of cognitive deterioration in Alzheimer's disease.

UR - https://www.scopus.com/pages/publications/0028120718

U2 - 10.1176/ajp.151.1.126

DO - 10.1176/ajp.151.1.126

M3 - Article

C2 - 8267111

AN - SCOPUS:0028120718

SN - 0002-953X

VL - 151

SP - 126

EP - 129

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

IS - 1

ER -

A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease

Abstract

Access to Document

Fingerprint

Cite this

A double-blind, placebo-controlled crossover study of ganglioside GM₁ treatment for Alzheimer's disease